Molecular identification of cardiomyocytes for cardiac cell therapy
By screening cardiomyocytes using single-cell ribonucleic acid sequencing and flow cytometry, a cell composition for low-risk arrhythmias was prepared, solving the problem of arrhythmias caused by cardiomyocyte grafts and improving the safety and efficacy of cardiac cell therapy.
CN122742877APending Publication Date: 2026-09-11BLUEROCK THERAPEUTICS LP
14 Cites 0 Cited by
Patent Information
- Application Number
- CN202480085478.0
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2023-12-22
- Filing Date
- 2024-12-20
- Publication Date
- 2026-09-11
AI Technical Summary
Technical Problem
In the prior art, cardiomyocyte grafts derived from pluripotent stem cells often induce arrhythmias after administration, and there is a lack of effective methods and compositions to mitigate graft-induced arrhythmias, which hinders the treatment of heart diseases and injuries.
Method used
By using single-cell RNA sequencing (scRNA-Seq) and flow cytometry, the molecular profile of cardiomyocytes was determined, cells with low risk of graft-induced arrhythmias were screened, and mature or immature cardiomyocyte compositions were prepared for cardiac cell therapy.
Benefits of technology
It significantly reduced the risk of arrhythmias induced by cardiomyocyte grafts and improved the safety and efficacy of cardiac cell therapy.
✦ Generated by Eureka AI based on patent content.
Abstract
The present disclosure relates generally to methods of screening and preparing cardiac cell therapies with low risk of causing graft-induced arrhythmia.
Need to check novelty before this filing date? Find Prior Art